Meta Pixel

NeuOrphan

Australia|Biotechnology

Overview

  • Multiple Sclerosis (MS) is an autoimmune disease that damages the myelin coating around nerve fibres, causing disruption of nerve signals and a variety of symptoms of variable severity. Myelin is the sleeve of fatty tissue that protects and insulates nerve fibres, like insulation around a wire. Myelin helps electrical signals travel along nerve fibres. Damage to myelin and nerve fibres is called demyelination. The scar tissue that results is called sclerosis. 
  • NeuOrphan has identified what we believe is a root cause of progressive Multiple Sclerosis—a deficiency in the brain’s thyroid hormone transporter, MCT8, which disrupts myelin repair by causing the death of myelin-producing cells (oligodendrocytes).
  • Our lead candidate, Dioprotectome™, is a small molecule that restores remyelination by bypassing the MCT8 pathway and protecting oligodendrocytes from immune damage. It has shown compelling results in both animal models and human cell studies, reversing neurological decline and promoting regeneration of damaged nerve fibres.
  • Unlike current MS treatments, which only suppress immune symptoms, Dioprotectome™ offers the potential to halt—and even reverse—the course of MS.

Investment highlights

  • Blockbuster drug potential driving potential for unicorn valuation
  • Scientific program significantly derisked after 15 years of research
  • Multiple exit opportunities
  • Huge social impact

Corporate website: https://neuorphan.com/

Problem and Solution

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.



Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.



Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.



Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.



Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante ut urna accumsan lacinia. Sed sed enim volutpat, malesuada metus ut, lobortis lectus. Sed vulputate fringilla justo, sed condim

Market Opportunity

Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.



Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.

Proin neque lacus, semper vel ex at, eleifend rhoncus est.

Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.


Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu.
Nullam sed dolor suscipit, efficitur

Competitive Advantage

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.



Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.



Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.



Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac

Highlights & Milestones

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.



Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.



Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.



Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar u

See more exiting opportunities on CapitalHQ

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

flag_new zealand
New Zealand NZD
Biotechnology Series B+

ProxyTwin

ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...

flag_australia
Australia AUD
Artificial Intelligence Seed Round

HorizonTwo Capital Partners

HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.

flag_australia
Australia AUD
Advanced Manufacturing Private Placement

The Insides Company

First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.

flag_new zealand
New Zealand AUD
Medical Devices Series A

DCARB

We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.

flag_australia
Australia CAD
Green Hydrogen Series B+

Grabba Technologies Pty Ltd

Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.

flag_australia
Australia AUD
Electronic Equipment & Instruments Private Placement

Join over 45,000+ sophisticated investors

Join Now